Stockreport

Mural Oncology Announces Plans to Explore Strategic Alternatives

Mural Oncology plc - Ordinary Shares  (MURA) 
PDF Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical develo [Read more]